Co-Diagnostics Statistics
Total Valuation
Co-Diagnostics has a market cap or net worth of 5.74 million. The enterprise value is -4.23 million.
| Market Cap | 5.74M |
| Enterprise Value | -4.23M |
Important Dates
The next estimated earnings date is Thursday, March 19, 2026.
| Earnings Date | Mar 19, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Co-Diagnostics has 2.03 million shares outstanding. The number of shares has increased by 11.72% in one year.
| Current Share Class | 2.03M |
| Shares Outstanding | 2.03M |
| Shares Change (YoY) | +11.72% |
| Shares Change (QoQ) | +14.45% |
| Owned by Insiders (%) | 5.08% |
| Owned by Institutions (%) | 12.33% |
| Float | 1.80M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 11.31 |
| PB Ratio | 0.14 |
| P/TBV Ratio | 0.42 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 0.13 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 0.13 |
Financial Position
The company has a current ratio of 3.81, with a Debt / Equity ratio of 0.04.
| Current Ratio | 3.81 |
| Quick Ratio | 3.36 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.05 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -62.12% and return on invested capital (ROIC) is -119.76%.
| Return on Equity (ROE) | -62.12% |
| Return on Assets (ROA) | -37.92% |
| Return on Invested Capital (ROIC) | -119.76% |
| Return on Capital Employed (ROCE) | -86.56% |
| Revenue Per Employee | 3,848 |
| Profits Per Employee | -243,799 |
| Employee Count | 132 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 0.28 |
Taxes
| Income Tax | -1.15M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -87.32% in the last 52 weeks. The beta is 1.26, so Co-Diagnostics's price volatility has been higher than the market average.
| Beta (5Y) | 1.26 |
| 52-Week Price Change | -87.32% |
| 50-Day Moving Average | 8.63 |
| 200-Day Moving Average | 9.57 |
| Relative Strength Index (RSI) | 29.18 |
| Average Volume (20 Days) | 150,124 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.10 |
Income Statement
In the last 12 months, Co-Diagnostics had revenue of 507,892 and -32.18 million in losses. Loss per share was -29.01.
| Revenue | 507,892 |
| Gross Profit | 172,843 |
| Operating Income | -35.53M |
| Pretax Income | -33.33M |
| Net Income | -32.18M |
| EBITDA | -34.33M |
| EBIT | -35.53M |
| Loss Per Share | -29.01 |
Balance Sheet
The company has 11.44 million in cash and 1.47 million in debt, with a net cash position of 9.97 million or 4.91 per share.
| Cash & Cash Equivalents | 11.44M |
| Total Debt | 1.47M |
| Net Cash | 9.97M |
| Net Cash Per Share | 4.91 |
| Equity (Book Value) | 39.83M |
| Book Value Per Share | 24.82 |
| Working Capital | 10.36M |
Cash Flow
In the last 12 months, operating cash flow was -31.17 million and capital expenditures -641,065, giving a free cash flow of -31.81 million.
| Operating Cash Flow | -31.17M |
| Capital Expenditures | -641,065 |
| Free Cash Flow | -31.81M |
| FCF Per Share | -15.67 |
Margins
| Gross Margin | 34.03% |
| Operating Margin | -6,995.70% |
| Pretax Margin | -6,562.78% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Co-Diagnostics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -11.72% |
| Shareholder Yield | -11.72% |
| Earnings Yield | -560.24% |
| FCF Yield | -553.77% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 2, 2026. It was a reverse split with a ratio of 0.0333333.
| Last Split Date | Jan 2, 2026 |
| Split Type | Reverse |
| Split Ratio | 0.0333333 |
Scores
Co-Diagnostics has an Altman Z-Score of -1.69 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.69 |
| Piotroski F-Score | 1 |